Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation
Conditions
Interventions
Intervention1: Group A receiving High Dose Dual Therapy
(the test group): Group A participants will receive cap omeprazole 20mg four times a day and cap amoxicillin 1g four times a day for 14 days.
Th
Sponsors
Intramural Research Fund Committee
Eligibility
Inclusion criteria
Inclusion criteria: All patients more than 18 years of age who undergo esophagogastroduodenoscopy for the investigation of gastrointestinal symptoms in the Department of Surgery, JIPMER and are tested positive for Helocobacter pylori infection.
Exclusion criteria
Exclusion criteria: 1. Previous eradication therapy. 2. Patients who have used antibiotics within the previous 4 weeks. 3. Past history of developing allergy to any antibiotic used in the study. 4. Patients who have undergone gastrectomy. 5. Coexisting of severe concomitant medical illness. 6. Pregnancy or lactating women. 7. Patients diagnosed with any malignancies. 8. Patients with portal gastropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study design is designed as a superiority trial. Aim is to compare the effectiveness of High Dose Dual Therapy in eradicating Helicobacter pylori infection. Aim is to prove that the proposed regimen is superior to the Standard Triple therapy in eradiacting the Helicobacter pylori Infection, with a level of significance of 5 percent and margin of superiority of 2 percent.Timepoint: 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the compliance & adverse effects of High Dose Dual Therapy & Standard Triple Therapy.Timepoint: 2 weeks | — |
Countries
India
Contacts
Public ContactDr Anandhi A
JMedical Education and Research
Outcome results
None listed